1. Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. Issue 3 (March 2020) Authors: Randrian, Violaine; Adenis, Antoine; Desrame, Jérôme; Barbier, Emilie; Di Fiore, Frédéric; Lièvre, Astrid; Dahan, Laetitia; Laurent-Puig, Pierre; Mineur, Laurent; Breysacher, Gilles; Roquin, Guillaume; Louafi, Samy; Lopez, Anthony; Louvet, Christophe; Borg, Christophe; Metges, Jean Philippe; Faro... Journal: Digestive and liver disease Issue: Volume 52:Issue 3(2020) Page Start: 347 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗